Ambrx
Dr. Sandra Aung will be responsible for overseeing the clinical development of the Ambrx pipeline. Dr. Aung brings over 20 years of experience in the pharmaceutical and biotechnology industry to her new role. Prior to Ambrx, Dr. Aung was Chief Clinical Development Officer at Oncosec Medical. Dr. Aung was previously with Nektar Therapeutics’ supporting the development of pegylated interleukin-2, and earlier in her career she held research and leadership positions at UbiVac, Inc. and Cell Genesys. Dr. Aung brings cross industry and academic relationships with Key Opinion Leaders (KOLs) and extensive drug development experience. Dr. Aung has a versatile background in autoimmunity, immune-oncology, and infectious disease and has authored over 30 peer-reviewed publications and received multiple Small Business Innovate Research (SBIR) grants from the National Cancer Institute/ National Institutes of Health.
Ambrx
Ambrx, Inc. is a biopharmaceutical company with a mission to deliver breakthrough protein therapeutics. Ambrx is based on a fundamental advance in protein biosynthesis that enables the company to genetically engineer proteins with new amino acid building blocks beyond the common twenty, enabling the biosynthesis of proteins with new physical, chemical and pharmacological properties.